What does research say about Semax?

Rat studies report that it binds in the basal forebrain, raises BDNF protein levels, and alters neurotrophin gene expression across hippocampus, frontal cortex and retina, including under induced ischaemia. Human clinical studies exist in stroke and cerebrovascular indications, published almost entirely in Russian.

Is Semax an approved medicine?

It is registered as a medicine in Russia and used clinically there. It has no marketing authorisation in the EU, the UK or the US, and no agency outside Russia has assessed it.

Why is Semax research hard to evaluate?

Because most of it is in Russian, in Russian journals, and often without an accessible English full text. Independent replication outside Russia, cross-language systematic review and second-agency regulatory assessment have largely not happened, and those are the mechanisms by which clinical claims normally become trusted internationally.

What is Semax made from?

It is a seven-amino-acid analogue of the ACTH(4-10) fragment, with a Pro-Gly-Pro tail replacing residues 8 to 10 to slow enzymatic breakdown. The parent fragment influences learning and memory in animal models without the hormonal activity of full-length ACTH.

Are there known side effects of Semax?

Safety data exists within the Russian clinical literature but is not readily verifiable from outside it, so this page does not summarise it. An empty adverse-findings list here reflects what can be checked, not a finding that nothing was reported.

Research guides

Semax: what the research says

An ACTH(4-10) analogue registered as a medicine in Russia and unknown to Western regulators. What the BDNF work reported, and why the English record looks thin.

Available in the catalogue

Supplied as research material. Sizes and pricing are on the product page. Availability is not a statement about what a compound does.

SEMAX
Nootropic & Cognitive

Semax presents a problem that is bibliographic rather than scientific. It has more human data behind it than most compounds in this catalogue, and that data is very hard for a reader outside Russia to evaluate.

What the molecule is

A seven-amino-acid peptide: residues 4 to 7 of adrenocorticotropic hormone, followed by a Pro-Gly-Pro tail that slows enzymatic breakdown. The tail stands in for residues 8 to 10 of the parent hormone, which is why the literature describes it as an analogue of ACTH(4–10).

The parent fragment is interesting because it influences learning and memory in animal models without the hormonal activity of full-length ACTH — the corticotropic function lives elsewhere in the molecule. Semax was developed to keep the first property and extend its duration.

The rodent work

The mechanistic literature centres on the neurotrophin system: brain-derived neurotrophic factor and nerve growth factor, and their receptors. Rat studies report that the peptide binds in the basal forebrain and increases BDNF protein levels, and that it alters expression of neurotrophin genes in hippocampus, frontal cortex and retina. Further work examined the same expression changes under induced cerebral ischaemia.

This is a coherent body of mechanistic work with a consistent proposed mechanism, and it is the strongest part of the compound's evidence base.

The human trials, and the language problem

Semax is registered as a medicine in Russia and is used there clinically, principally in stroke and cerebrovascular indications. Clinical studies have been published — including work by Gusev and colleagues on patients at different stages of ischaemic stroke, and on progression in cerebrovascular insufficiency.

Nearly all of it is in Russian, in Russian journals, and much of it is not indexed with an English full text. That is not a criticism of the work; it is a description of what a reader in Finland or elsewhere in the EU can actually verify. The usual mechanisms by which a clinical claim becomes trusted internationally — independent replication in another country, systematic review across languages, regulatory assessment by a second agency — have largely not happened here.

Semax has no marketing authorisation in the EU, the UK or the US. Its registration in Russia is a real regulatory approval by a real agency, and it is also the only one.

What studies reported

Each entry states what a study examined and the model it used. Nothing below describes an outcome for a person.

Everything below is drawn from published research, and each entry names the model the study used. Approval status varies by compound and by country, and nothing described here is supplied as a medicine or for use in a person.

Dolotov et al. (2006)Journal of Neurochemistry
Reported specific binding of the peptide and increased levels of brain-derived neurotrophic factor protein.
rat basal forebrain Source
Shadrina et al. (2010)Journal of Molecular Neuroscience · 41(1):30–5
Compared the time course of NGF and BDNF gene expression across three brain regions under the peptide's action.
rat hippocampus, frontal cortex and retina Source
Stavchansky et al. (2011)Molecular Biology (Moscow) · 45(6):1026–35
Examined the effect of the peptide and of its C-terminal PGP fragment on expression of neurotrophins and their receptors during induced ischaemia. Published in Russian.
rat, incomplete global cerebral ischaemia Source
Gusev et al. (2018)Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · 118(3 Vyp 2):61–8
Assessed the peptide's efficacy in ischaemic stroke across disease stages. Published in Russian.
human, patients at different stages of ischaemic stroke Source

Adverse and null findings reported

No dedicated safety study has been published for this compound. That is not a finding that none exists — it means the question has not been asked in print, and the gaps below say so.

What the research does not establish

An absence cannot be cited, so these are stated plainly. They are the part of the picture that silence would otherwise hide.

The clinical evidence base is almost entirely Russian-language and has not been independently replicated outside Russia, so it has not been through the cross-checking that normally establishes a clinical claim internationally.
No regulatory agency outside Russia has assessed the compound. The EMA, MHRA and FDA have not evaluated it, and it holds no marketing authorisation in the EU.
The adverse list is empty because dedicated safety studies are not available in a language most readers of this page can check, not because none exist or because none found anything.
Trial methodology in the available clinical literature is difficult to assess from abstracts alone, and full texts are frequently not accessible in translation.
The rodent neurotrophin work is mechanistic and does not measure behavioural or cognitive outcomes in humans, so it supports a proposed mechanism rather than an effect.

Common questions

What does research say about Semax?: Rat studies report that it binds in the basal forebrain, raises BDNF protein levels, and alters neurotrophin gene expression across hippocampus, frontal cortex and retina, including under induced ischaemia. Human clinical studies exist in stroke and cerebrovascular indications, published almost entirely in Russian.
Is Semax an approved medicine?: It is registered as a medicine in Russia and used clinically there. It has no marketing authorisation in the EU, the UK or the US, and no agency outside Russia has assessed it.
Why is Semax research hard to evaluate?: Because most of it is in Russian, in Russian journals, and often without an accessible English full text. Independent replication outside Russia, cross-language systematic review and second-agency regulatory assessment have largely not happened, and those are the mechanisms by which clinical claims normally become trusted internationally.
What is Semax made from?: It is a seven-amino-acid analogue of the ACTH(4-10) fragment, with a Pro-Gly-Pro tail replacing residues 8 to 10 to slow enzymatic breakdown. The parent fragment influences learning and memory in animal models without the hormonal activity of full-length ACTH.
Are there known side effects of Semax?: Safety data exists within the Russian clinical literature but is not readily verifiable from outside it, so this page does not summarise it. An empty adverse-findings list here reflects what can be checked, not a finding that nothing was reported.

Compounds covered

The reference page for each compound this article discusses.

Semax

BPC-157: what the research says
Body Protection Compound 157 has a large rodent literature and almost no human data. What the studies measured, in which models, and the caveat behind them.
Ipamorelin: what the research says
A selective growth hormone secretagogue with a completed, published human trial. It missed its primary endpoint, and that is the most useful result it has.
Peptide shelf life and stability
How long lyophilised and reconstituted peptides keep, and the four things that shorten it: temperature, moisture, light and oxidation. Storage figures included.

About this article

Everything reported here comes from published research, and each finding names the model the study used — cell culture, rat, or human. Findings in one model do not transfer to another, most of the work described is preclinical, and none of it is a claim that a compound is safe or effective for any purpose. Nothing on this page describes doses, routes of administration, or use in a person.

Approval status varies by compound and by country. A few of the substances described are the active ingredient of medicines authorised in the EU; most have no marketing authorisation anywhere and have never been assessed by a regulator. Neither is supplied as a medicine here. All material supplied by ASSAY is sold for in-vitro laboratory research only, and is not a drug, food, cosmetic or medical device, and not for human or veterinary use.

All guides